ERBB2 and breast cancer: This is consistent with the findings in the Nurses’ Health Study [49], but inconsistent with a case–control study from the Breast Cancer Family Registry [50] and a Korean cohort study [48], which reported that parity was associated with an increased risk of the HER2-positive subtype.